Holen Sie sich die Stockscreener-App
9.56
0.52%
-0.05
Handel nachbörslich:
9.54
-0.02
-0.21%
Schlusskurs vom Vortag:
$9.61
Offen:
$9.7
24-Stunden-Volumen:
3.97M
Relative Volume:
0.93
Marktkapitalisierung:
$877.35M
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.7445
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+3.91%
1M Leistung:
+2.52%
6M Leistung:
-20.13%
1J Leistung:
-58.78%
1-Tages-Spanne:
$9.51
$10.14
1-Wochen-Bereich:
$8.875
$10.14
52-Wochen-Spanne:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.56 | 877.35M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus
Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks
Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener
Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.
Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks
California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush - Defense World
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '25 |
Sale |
12.18 |
6,502 |
79,194 |
59,878 |
| LEONARD JOHN M | President and CEO |
Jan 03 '25 |
Sale |
12.18 |
26,807 |
326,509 |
941,115 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '25 |
Sale |
12.18 |
8,966 |
109,206 |
77,388 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '25 |
Sale |
12.18 |
7,422 |
90,400 |
64,048 |
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):